Email Us
Call Us
AUSTIN, TX, December 17, 2018
Altogen Labs, a biotechnology laboratory focused on the development of innovative cancer therapeutics, today announced the addition of new CDX models (MDA-MB-157, MDA-MB-453, U87, and OVCAR-3). The addition of these xenograft models further increases Altogen Labs’ product line in breast and ovarian cancer, as well as glioblastoma to 89 CDX, 29 PDX, and over 40 syngeneic in-house validated xenograft models.
Animal xenograft systems have been effective in creating new insights into the mechanisms that promote the development of the disease. Xenograft studies accelerate the advancement of innovative cancer therapies by providing a more accurate model of tumor development compared to in vitro studies. Xenograft models continue to be a method of choice for examining the response to antineoplastic agents in a live organism. The ability of immunocompromised rodents to maintain the growth of human neoplasms contributes significantly to a transition from preclinical studies to clinical trials and promotes the development of new anti-cancer therapeutics.
Our highly qualified scientists have established a wide array of animal models and employ numerous xenotransplantation approaches relevant to the molecular mechanism of action. Subcutaneous, orthotopic, intramuscular, intravenous, intraperitoneal, or intratracheal routes of administration can be used, depending on the needs of the experiment. Altogen Labs team provides clients with expert knowledge and a comprehensive suite of laboratory services, including the selection of an appropriate cancer model, observation of experimental subjects and post-experimental analysis. Skilled personnel conducts all laboratory studies in an IACUC-regulated facility.
About Altogen Labs
Altogen Labs is a GLP-compliant contract research organization headquartered in Austin, Texas (USA) that offers a diverse range of oncology models and in vivo preclinical pharmacology services for industry and academic clients. Altogen Labs is a global provider of preclinical research services for pharmaceutical companies, cancer research centers, and biotechnology companies. Our services include IC50 assays, stable-cell line engineering, in-vivo RNAi and tissue-targeted siRNA delivery, gene function and expression analysis, transient and stable transfections of cell lines, engineering of RNAi knockdown cell lines, microfluidics-based RNA and DNA liposome encapsulation, and cell-based assay development.
For more information, please visit: www.altogenlabs.com
Altogen Labs
11200 Manchaca Road, Suite 203
Austin TX 78748
www.AltogenLabs.com
info@altogenlabs.com